Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMETEK INC/AME · Entity 3025 | Executive VP- CFO | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMETEK INC/
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,528 |
Ending reported balance
After 2026-03-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-19 · Tax withholding · Disposed 237 · Balance 11,595 F1: Represents withholding of shares to pay taxes. Row 2 · 2026-03-22 · Tax withholding · Disposed 67 · Balance 11,528 F1: Represents withholding of shares to pay taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares to pay taxes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LANXESS Solutions US Inc.
Report date April 21, 2017 · Filed April 24, 2017
Section 16 reporting ended · disclosed 2017-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-04-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-04-21 · Disposition to issuer · Disposed 10,496 · Balance 5,186 F1: On September 25, 2016, Chemtura Corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lanxess Deutschland GmbH ("Lanxess") and LANXESS Solutions US Inc. (f/k/a LANXESS Additives Inc.) ("Merger Subsidiary"), pursuant to which Merger Subsidiary will merge (the "Merger") with and into the Company, whereupon the existence of Merger Subsidiary will cease and the Company will become the surviving corporation and a wholly-owned subsidiary of Lanxess. The Merger became effective on April 21, 2017 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Company's common stock, par value $0.01, outstanding immediately prior to the Effective Time was converted into the right to receive $33.50 in cash, without interest (the "Merger Consideration"). Row 2 · 2017-04-21 · Disposition to issuer · Disposed 5,186 · Balance 0 F1: On September 25, 2016, Chemtura Corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lanxess Deutschland GmbH ("Lanxess") and LANXESS Solutions US Inc. (f/k/a LANXESS Additives Inc.) ("Merger Subsidiary"), pursuant to which Merger Subsidiary will merge (the "Merger") with and into the Company, whereupon the existence of Merger Subsidiary will cease and the Company will become the surviving corporation and a wholly-owned subsidiary of Lanxess. The Merger became effective on April 21, 2017 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Company's common stock, par value $0.01, outstanding immediately prior to the Effective Time was converted into the right to receive $33.50 in cash, without interest (the "Merger Consideration"). F2: Represents unvested restricted stock units ("RSUs") that were automatically cancelled in connection with the Merger and converted to a deferred cash award in an amount equal to the product of the Merger Consideration and the number of shares represented by such RSUs (the "Deferred Cash Award"). The Deferred Cash Award continues to be subject to the same terms and conditions of the RSUs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the RSUs prior to the Effective Time. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $15.38 · Expires 2022-03-01 | Direct | 0 |
Reported balance
After 2017-04-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-21 · Disposition to issuer · Disposed 1,781 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase Common Stock that was outstanding prior to the Effective Time was cancelled and converted into the right to receive a cash payment equal to the product of (A) the number of shares of Common Stock underlying such option and (B) the excess, if any, of the Merger Consideration over the applicable exercise price of such option. |
| Employee Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2023-03-01 | Direct | 0 |
Reported balance
After 2017-04-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-04-21 · Disposition to issuer · Disposed 5,130 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase Common Stock that was outstanding prior to the Effective Time was cancelled and converted into the right to receive a cash payment equal to the product of (A) the number of shares of Common Stock underlying such option and (B) the excess, if any, of the Merger Consideration over the applicable exercise price of such option. |
| Performance SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-04-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-04-21 · Disposition to issuer · Disposed 8,076 · Balance 0 F4: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 25, 2016, Chemtura Corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lanxess Deutschland GmbH ("Lanxess") and LANXESS Solutions US Inc. (f/k/a LANXESS Additives Inc.) ("Merger Subsidiary"), pursuant to which Merger Subsidiary will merge (the "Merger") with and into the Company, whereupon the existence of Merger Subsidiary will cease and the Company will become the surviving corporation and a wholly-owned subsidiary of Lanxess. The Merger became effective on April 21, 2017 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Company's common stock, par value $0.01, outstanding immediately prior to the Effective Time was converted into the right to receive $33.50 in cash, without interest (the "Merger Consideration").
F2: Represents unvested restricted stock units ("RSUs") that were automatically cancelled in connection with the Merger and converted to a deferred cash award in an amount equal to the product of the Merger Consideration and the number of shares represented by such RSUs (the "Deferred Cash Award"). The Deferred Cash Award continues to be subject to the same terms and conditions of the RSUs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the RSUs prior to the Effective Time.
F3: Pursuant to the terms of the Merger Agreement, each option to purchase Common Stock that was outstanding prior to the Effective Time was cancelled and converted into the right to receive a cash payment equal to the product of (A) the number of shares of Common Stock underlying such option and (B) the excess, if any, of the Merger Consideration over the applicable exercise price of such option.
F4: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 22, 2026 Filed Mar 23, 2026 12:48 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 67 | $209.37 | $14,027.79 |
DisclosureSEC source: 0001037868-26-000121 · wk-form4_1774270091.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,528 F1 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 12:48 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 237 | $211.50 | $50,125.50 |
DisclosureSEC source: 0001037868-26-000121 · wk-form4_1774270091.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,595 F1 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:11 UTC | AMETEK INC/ AME · Entity 3025 | GrantStock Option · Derivative | 11,960 | $0.00 Strike: $212.77 | $0.00 |
DisclosureSEC source: 0001037868-26-000104 · wk-form4_1773954686.xml · derivative · entry 3 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,960 Underlying: Common Stock · 11,960 shares Expires 2036-03-18 F3 · derivative.exercise_date: The stock options will become exercisable in three equal annual installments beginning on March 18, 2027. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:11 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 335 | $212.77 | $71,277.95 |
DisclosureSEC source: 0001037868-26-000104 · wk-form4_1773954686.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,832 F2 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 18, 2026 Filed Mar 19, 2026 21:11 UTC | AMETEK INC/ AME · Entity 3025 | GrantCommon Stock | 3,780 | $212.77 | $804,270.60 |
DisclosureSEC source: 0001037868-26-000104 · wk-form4_1773954686.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,167 F1 · kind: Constitutes restricted stock issued under the AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:12 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 103 | $233.33 | $24,032.99 |
DisclosureSEC source: 0001037868-26-000045 · wk-form4_1771535542.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,387 F2 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:12 UTC | AMETEK INC/ AME · Entity 3025 | GrantCommon Stock | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0001037868-26-000045 · wk-form4_1771535542.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,490 F1 · kind: Settlement of PRSUs awarded on March 22, 2023. Read SEC document |
| March 22, 2025 Filed Mar 24, 2025 20:13 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 67 | $174.52 | $11,692.84 |
DisclosureSEC source: 0001127602-25-010276 · form4.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,117 F1 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 20:13 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 89 | $174.52 | $15,532.28 |
DisclosureSEC source: 0001127602-25-010276 · form4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,184 F1 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 13:11 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 237 | $177.07 | $41,965.59 |
DisclosureSEC source: 0001127602-25-010063 · form4.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,273 F2 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 13:11 UTC | AMETEK INC/ AME · Entity 3025 | GrantStock Option · Derivative | 11,190 | $0.00 Strike: $176.08 | $0.00 |
DisclosureSEC source: 0001127602-25-010063 · form4.xml · derivative · entry 3 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,190 Underlying: Common Stock · 11,190 shares Expires 2035-03-18 F3 · derivative.exercise_date: The stock options will become exercisable in three equal annual installments beginning on March 18, 2026. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 13:11 UTC | AMETEK INC/ AME · Entity 3025 | GrantCommon Stock | 3,650 | $176.08 | $642,692.00 |
DisclosureSEC source: 0001127602-25-010063 · form4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,510 F1 · kind: Constitutes restricted stock issued under the AMETEK, Inc. 2020 Omnibus Incentive Compensation Plan. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 13:51 UTC | AMETEK INC/ AME · Entity 3025 | Tax withholdingCommon Stock | 146 | $188.78 | $27,561.88 |
DisclosureSEC source: 0001127602-25-006139 · form4.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,860 F2 · kind: Represents withholding of shares to pay taxes. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 13:51 UTC | AMETEK INC/ AME · Entity 3025 | GrantCommon Stock | 531 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006139 · form4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · Executive VP- CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,006 F1 · kind: Settlement of PRSU's awarded on March 13, 2022. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 09:11 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Disposition to issuerPerformance Shares · Derivative | 8,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-010787 · doc4.xml · derivative · entry 5 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,076 shares Expires not disclosed F4 · derivative.exercise_price: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time. F4 · price: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time. F4 · derivative.exercise_date: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time. F4 · derivative.expiration_date: Represents performance share awards relating to Common Stock ("PSAs") that were automatically converted in connection with the Merger to an amount equal to the product of the Merger Consideration and the number of shares represented by such PSAs, which number is based on the target performance level (the "PS Consideration"); provided, however, that in the case of PSAs for which the applicable performance period had not ended as of the Effective Time, such PSAs were converted to a deferred cash award equal to the PS Consideration and continue to be subject to the same terms and conditions of the PSAs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the PSAs prior to the Effective Time. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 09:11 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Disposition to issuerEmployee Stock Option (right to purchase) · Derivative | 5,130 | $13.00 Strike: $20.50 | $66,690.00 |
DisclosureSEC source: 0000899243-17-010787 · doc4.xml · derivative · entry 4 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,130 shares Expires 2023-03-01 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase Common Stock that was outstanding prior to the Effective Time was cancelled and converted into the right to receive a cash payment equal to the product of (A) the number of shares of Common Stock underlying such option and (B) the excess, if any, of the Merger Consideration over the applicable exercise price of such option. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 09:11 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Disposition to issuerEmployee Stock Option (right to purchase) · Derivative | 1,781 | $18.12 Strike: $15.38 | $32,271.72 |
DisclosureSEC source: 0000899243-17-010787 · doc4.xml · derivative · entry 3 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,781 shares Expires 2022-03-01 F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase Common Stock that was outstanding prior to the Effective Time was cancelled and converted into the right to receive a cash payment equal to the product of (A) the number of shares of Common Stock underlying such option and (B) the excess, if any, of the Merger Consideration over the applicable exercise price of such option. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 09:11 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Disposition to issuerCommon Stock | 5,186 | $33.50 | $173,731.00 |
DisclosureSEC source: 0000899243-17-010787 · doc4.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On September 25, 2016, Chemtura Corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lanxess Deutschland GmbH ("Lanxess") and LANXESS Solutions US Inc. (f/k/a LANXESS Additives Inc.) ("Merger Subsidiary"), pursuant to which Merger Subsidiary will merge (the "Merger") with and into the Company, whereupon the existence of Merger Subsidiary will cease and the Company will become the surviving corporation and a wholly-owned subsidiary of Lanxess. The Merger became effective on April 21, 2017 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Company's common stock, par value $0.01, outstanding immediately prior to the Effective Time was converted into the right to receive $33.50 in cash, without interest (the "Merger Consideration"). F2 · shares: Represents unvested restricted stock units ("RSUs") that were automatically cancelled in connection with the Merger and converted to a deferred cash award in an amount equal to the product of the Merger Consideration and the number of shares represented by such RSUs (the "Deferred Cash Award"). The Deferred Cash Award continues to be subject to the same terms and conditions of the RSUs as in effect immediately prior to the Effective Time and will be paid solely in cash in accordance with the vesting and payment schedule applicable to the RSUs prior to the Effective Time. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 09:11 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Disposition to issuerCommon Stock | 10,496 | $33.50 | $351,616.00 |
DisclosureSEC source: 0000899243-17-010787 · doc4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,186 F1 · kind: On September 25, 2016, Chemtura Corporation (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lanxess Deutschland GmbH ("Lanxess") and LANXESS Solutions US Inc. (f/k/a LANXESS Additives Inc.) ("Merger Subsidiary"), pursuant to which Merger Subsidiary will merge (the "Merger") with and into the Company, whereupon the existence of Merger Subsidiary will cease and the Company will become the surviving corporation and a wholly-owned subsidiary of Lanxess. The Merger became effective on April 21, 2017 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Company's common stock, par value $0.01, outstanding immediately prior to the Effective Time was converted into the right to receive $33.50 in cash, without interest (the "Merger Consideration"). Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:05 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | GrantPerformance Shares · Derivative | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006343 · doc4.xml · derivative · entry 2 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,259 Underlying: Common Stock · 2,259 shares Expires 2020-03-01 F2 · derivative.exercise_price: Grant of performance shares. Each performance share represents a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock. The number of shares reported represents the target amount. The actual number of shares to be delivered will be based on Chemtura Corporation's total shareholder return over the three-year vesting period relative to all companies in the Dow Jones US Chemical Index and could equal 200% of the target amount. The performance shares will settle as soon as practicable after December 31, 2019 but no later than March 1, 2020. F2 · derivative.exercise_date: Grant of performance shares. Each performance share represents a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock. The number of shares reported represents the target amount. The actual number of shares to be delivered will be based on Chemtura Corporation's total shareholder return over the three-year vesting period relative to all companies in the Dow Jones US Chemical Index and could equal 200% of the target amount. The performance shares will settle as soon as practicable after December 31, 2019 but no later than March 1, 2020. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:05 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | GrantCommon Stock | 2,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006343 · doc4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,682 F1 · shares: Grant of restricted stock units. The restricted stock units vest in three equal installments: March 1, 2018; March 1, 2019; and March 1, 2020. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 16:20 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Exercise / conversionPerformance Shares · Derivative | 4,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-001455 · doc4.xml · derivative · entry 3 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,218 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share was granted in 2014 and represented a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock based on Chemtura Corporation's total shareholder return against the companies comprising the Dow Jones US Chemical Index (the "TSR Metric"). 4,202 shares of common stock represented the target amount of the award granted in 2014. The performance shares vested at 148% of the target amount based on the TSR Metric, for a total payout of 6,218 shares of common stock. F1 · price: Each performance share was granted in 2014 and represented a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock based on Chemtura Corporation's total shareholder return against the companies comprising the Dow Jones US Chemical Index (the "TSR Metric"). 4,202 shares of common stock represented the target amount of the award granted in 2014. The performance shares vested at 148% of the target amount based on the TSR Metric, for a total payout of 6,218 shares of common stock. F1 · derivative.exercise_date: Each performance share was granted in 2014 and represented a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock based on Chemtura Corporation's total shareholder return against the companies comprising the Dow Jones US Chemical Index (the "TSR Metric"). 4,202 shares of common stock represented the target amount of the award granted in 2014. The performance shares vested at 148% of the target amount based on the TSR Metric, for a total payout of 6,218 shares of common stock. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 16:20 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Tax withholdingCommon Stock | 2,319 | $33.15 | $76,874.85 |
DisclosureSEC source: 0000899243-17-001455 · doc4.xml · nonDerivative · entry 2 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,423 Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 16:20 UTC | LANXESS Solutions US Inc. CHMT · Entity 176782 | Exercise / conversionCommon Stock | 6,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-001455 · doc4.xml · nonDerivative · entry 1 Puri Dalip · CIK 0001505873 · VP and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share was granted in 2014 and represented a contingent right to receive between 0 and 2 shares of Chemtura Corporation common stock based on Chemtura Corporation's total shareholder return against the companies comprising the Dow Jones US Chemical Index (the "TSR Metric"). 4,202 shares of common stock represented the target amount of the award granted in 2014. The performance shares vested at 148% of the target amount based on the TSR Metric, for a total payout of 6,218 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.